TACE联合放射性125I粒子植入治疗原发性肝癌合并门静脉癌栓

目的探讨对原发性肝癌合并门静脉癌栓患者行TACE联合放射性~(125)I粒子植入治疗的安全性和有效性。方法回顾性分析50例原发性肝癌合并门静脉癌栓患者,其中22例接受TACE联合放射性~(125)I粒子植入治疗(实验组),28例仅接受TACE治疗(对照组)。采用Kaplan-Meier法评价两组患者远期疗效;观察门静脉再通情况和不良反应。结果实验组和对照组中位生存期分别为8.7个月和6.0个月;两组累积生存率差异有统计学意义(P=0.012)。治疗后实验组与对照组门静脉再通、腹腔积液发生率差异有统计学意义(P均0.05),而恶心、呕吐、腹痛、腹泻、便秘、手足麻木发生率差异无统计学意义(P均0.05)。结论 TACE联合放射性~(125)I粒子植入治疗原发性肝癌合并门静脉癌栓安全可行。

TACE combined with radioactive 125I particle implantation in treatment of primary liver cancer with portal venous tumor emboli

Objective To explore the safety and effectiveness of TACE combined with radioactive ¹²⁵I particle implantation in treatment of primary liver cancer with portal venous tumor emboli. Methods A total of 50 patients with primary liver cancer with portal venous tumor emboli were analyzed retrospectively, including 22 patients underwent TACE combined with radioactive ¹²⁵I particle implantation of portal vein (experimental group), 28 patients only underwent TACE (control group). The postoperative long-term curative effect were evaluated by Kaplan-Meier analysis, and portal venous recanalization and adverse reactions were observed. Results The median survival time of experimental group and control group was 8.7 and 6.0 months, respectively, and the difference of survival rate was statistically significant (P=0.012). The differences of incidence rate of portal venous recanalization, ascites between experimental group and control group was statistically significant (both P<0.05), while the differences of incidence rate of nausea and vomiting, abdominal pain, diarrhea, constipation, extremities numbness had no statistical significance (P>0.05). Conclusion TACE combined with radioactive ¹²⁵I particle implantation in treatment of primary liver cancer with portal venous tumor emboli is safe and feasible.